Literature DB >> 6809356

Pharmacokinetics of mitomycin C in rabbit and human.

G A van Hazel, J S Kovach.   

Abstract

A sensitive and specific high-pressure liquid chromatographic assay was developed to characterize the plasma elimination and urinary excretion of mitomycin C in humans. Extraction of mitomycin C and an internal standard, porfiromycin, from plasma by chromatography over a non-ionic resin, Porapak Q, yields high recovery of both compounds and facilitates measurement of as little as 5 ng mitomycin C by reversed-phase high-pressure liquid chromatography. The assay was used to characterize the plasma elimination of mitomycin C in rabbits and was shown to be applicable to the characterization of the pharmacokinetics of mitomycin C in humans receiving as little as 8 mg/m2.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6809356     DOI： 10.1007/BF00255482

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  11 in total

1.  [ACTION OF MITOMYCIN C IN 65 CASES OF MALIGNANT TUMOR. COMPARISON OF REPEATED SMALL DOSES AND "MASSIVE" DOSES].

Authors:  Y KENIS; P STRYCKMANS
Journal:  Chemotherapia (Basel)       Date:  1964

2.  Pharmacology of mitomycin C. III. In vitro metabolism by rat liver.

Authors:  H S SCHWARTZ
Journal:  J Pharmacol Exp Ther       Date:  1962-05       Impact factor: 4.030

3.  Studies on mitomycin C, especially method of administration.

Authors:  T HATA; C HOSSENLOPP; H TAKITA
Journal:  Cancer Chemother Rep       Date:  1961-07

4.  Mitomycin C (NSC-26980)--an evaluation of the Japanese reports.

Authors:  W FRANK; A E OSTERBERG
Journal:  Cancer Chemother Rep       Date:  1960-11

5.  Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung.

Authors:  M K Samson; R L Comis; L H Baker; S Ginsberg; R J Fraile; S T Crooke
Journal:  Cancer Treat Rep       Date:  1978-01

6.  Evaluation of dosage schedules of mitomycin C (NSC-26980) in children.

Authors:  W W Sutow; J R Wilbur; T J Vietti; P Vuthibhagdee; T Fujimoto; A Watanabe
Journal:  Cancer Chemother Rep       Date:  1971-06

7.  Clinical experience with mitomycin C in large infrequent doses.

Authors:  T E Godfrey; D W Wilbur
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

8.  Determination of mitomycin C in biomedical specimens by high-performance liquid chromatography.

Authors:  A Kono; Y Hara; S Eguchi; M Tanaka; Y Matsushima
Journal:  J Chromatogr       Date:  1979-11-11

9.  Phase II study of profiromycin vs mitomycin-C utilizing acute intermittent schedules.

Authors:  L H Baker; R M Izbicki; V K Vaitkevicius
Journal:  Med Pediatr Oncol       Date:  1976

10.  Mitomycin C and vinblastine chemotherapy for advanced breast cancer.

Authors:  P H Konits; J Aisner; D A van Echo; K Lichtenfeld; P H Wiernik
Journal:  Cancer       Date:  1981-09-15       Impact factor: 6.860
View more
  4 in total

1.  Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung.

Authors:  R G Buice; H B Niell; P Sidhu; B J Gurley
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

2.  Clinical pharmacokinetics of high-dose mitomycin C.

Authors:  R B Schilcher; J D Young; V Ratanatharathorn; C Karanes; L H Baker
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.

Authors:  S Kerpel-Fronius; J Verwey; M Stuurman; B Kanyár; P Lelieveld; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Pharmacokinetics of mitomycin C in patients after bolus injection and chemobolisation of the hepatic artery with Spherex starch particles.

Authors:  M J Czejka; W Jäger; J Schüller
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.